ADC Therapeutics SA: ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting

Multiple presentations will highlight the clinical utility of ZYNLONTA (loncastuximab tesirine-lpyl) in DLBCL and Cami (camidanlumab tesirine) in Hodgkin lymphoma ADC Therapeutics SA (NYSE: ADCT)

Related Keywords

Louisiana ,United States ,New Orleans ,New Jersey ,United Kingdom ,Texas ,San Francisco Bay ,California ,Switzerland ,London ,City Of ,San Francisco ,American ,Rituximab Lonca ,Loncastuximab Tesirine ,Jason Westin ,Amanda Loshbaugh ,Alexf Herrera ,Paolof Caimi ,Jenny Yeung ,Lausanne Biop ,Camidanlumab Tesirine Cami ,Eugenia Litz ,Nitin Jain ,Camidanlumab Tesirine ,Mary Ann Ondish ,Dai Chihara ,Mehdi Hamadani ,Francesco Vallania ,Company On Twitter ,Linkedin ,Marrow Transplant Program ,American Society Of Hematology ,Leukemic Properties ,Department Of Lymphoma Myeloma ,Taussig Cancer Institute ,Department Of Leukemia ,Cleveland Clinic Foundation ,Department Of Hematology ,Division Of Hematology ,University Of Texas Md Anderson Cancer Center ,Drug Administration ,Cancer Institute ,Ernestn Morial Convention Center ,College Of Wisconsin ,Outcomes Research ,Ernestn Morial Convention Center On ,Health Outcomes ,Institute Of Child Health ,City Of Hope Comprehensive Cancer Center ,American Society ,Annual Meeting ,World Effectiveness ,Economic Impact Associated ,Refractory Diffuse Largeb Cell Lymphoma ,Research Lymphoid Malignancies ,Stem Cell Transplantation ,Session Time ,Convention Center ,Cancer Center ,Antibody Drug Conjugate Bound ,Adult Patients ,Refractoryb Cell Acute Lymphoblastic Leukemia ,Lymphoblastic Leukemias ,Excluding Transplantation ,Clinical Trials ,Quantitative Systems Pharmacology Modeling ,Open Label Study ,Previously Untreated ,Frail Patients ,Diffuse Largeb Cell Lymphoma ,Prospective Therapeutic Trials ,World Outcomes ,Who Received Polatuzumab Vedotin ,Tafasitamab Plus Lenalidomide By Line ,Medical College ,Predictive Biomarkers ,Factors Influencing Efficacy ,Refractory Classical Hodgkin Lymphoma ,Hematopoietic Cell Transplantation ,Hope Comprehensive Cancer Center ,Potential Predictors ,Clinical Response ,Drug Conjugates As Targeted Conditioning Agents ,Gene Therapy ,Potent Anti Leukemic Properties ,Ormond Street Institute ,Child Health ,San Francisco Bay Area ,Ann Ondish ,Therapeutics ,Nnounces ,Abstracts ,Accepted ,Presentation ,4th ,Nnual ,Meeting ,